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LyOBJECTIVES The goal of this study was to develop a risk score model for patients with Brugada syndrome (BrS).
BACKGROUND Risk stratification in BrS is a significant challenge due to the low event rates and conflicting evidence.
METHODS A multicenter international cohort of patients with BrS and no previous cardiac arrest was used to evaluate
the role of 16 proposed clinical or electrocardiogram (ECG) markers in predicting ventricular arrhythmias (VAs)/sudden
cardiac death (SCD) during follow-up. Predictive markers were incorporated into a risk score model, and this model was
validated by using out-of-sample cross-validation.
RESULTS A total of 1,110 patients with BrS from 16 centers in 8 countries were included (mean age 51.8  13.6 years;
71.8% male). Median follow-up was 5.33 years; 114 patients had VA/SCD (10.3%) with an annual event rate of 1.5%. Of
the 16 proposed risk factors, probable arrhythmia–related syncope (hazard ratio [HR]: 3.71; p < 0.001), spontaneous
type 1 ECG (HR: 3.80; p < 0.001), early repolarization (HR: 3.42; p < 0.001), and a type 1 Brugada ECG pattern in
peripheral leads (HR: 2.33; p < 0.001) were associated with a higher risk of VA/SCD. A risk score model incorporating
these factors revealed a sensitivity of 71.2% (95% confidence interval: 61.5% to 84.6%) and a specificity of 80.2%
(95% confidence interval: 75.7% to 82.3%) in predicting VA/SCD at 5 years. Calibration plots showed a mean prediction
error of 1.2%. The model was effectively validated by using out-of-sample cross-validation according to country.
CONCLUSIONS This multicenter study identified 4 risk factors for VA/SCD in a primary prevention BrS population.
A risk score model was generated to quantify risk of VA/SCD in BrS and inform implantable cardioverter-
defibrillator prescription. (J Am Coll Cardiol EP 2021;7:210–22) © 2021 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 2405-500X https://doi.org/10.1016/j.jacep.2020.08.032
m aThe Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom; bFarr Institute of Health Informatics Research,
iversity College London, London, United Kingdom; cRoyal Papworth Hospital NHS Foundation Trust, Cambridge, United
gdom; dCardiology Department, European Georges Pompidou Hospital, Paris, France; eParis Descartes University, Paris,
nce; fParis Cardiovascular Research Center (INSERM U970), Paris, France; gInherited Cardiac Disease Unit, University Hospital
gen Arrixaca, Murcia, Spain; hRhythmology Department, Hôpital Cardiovasculaire Louis Pradel, Claude Bernard University,
on, France; iCardiology Department, Coimbra Hospital and University Centre, Coimbra, Portugal; jLaboratory of Cardiovascular
J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 7 , N O . 2 , 2 0 2 1 Honarbakhsh et al.
F E B R U A R Y 2 0 2 1 : 2 1 0 – 2 2 Brugada Syndrome Risk Stratification
211AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial fibrillation
AUC = area under the curve
BrS = Brugada syndrome
CI = confidence interval
ECG = electrocardiogram
ER = early repolarization
HC = Harrell’s C
ICD = implantable
cardioverter-defibrillator
NNT = number needed to treat
PAR = probable arrhythmia–
related
SCD = sudden cardiac death
SND = sinus node disease
VA = ventricular arrhythmia
VERP = ventricular effectiveB rugada syndrome (BrS) is an inherited cardiacchannelopathy, diagnosed by coved ST-segment elevation in electrocardiogram
(ECG) leads V1 to V3 in structurally normal hearts
with a prevalence of 1 to 30 per 10,000 depending
on ethnicity (1). It is associated with ventricular ar-
rhythmias (VAs) and sudden cardiac death (SCD).
Risk assessment is challenging, especially in initially
asymptomatic cases (2,3). Several clinical and ECG
markers have been proposed, but these are mainly
derived from single-center studies with no validation
in other cohorts (4–9). No study has provided a
comprehensive assessment of all proposed risk fac-
tors in an international multicenter cohort.
The goal of the current study was to review the
major proposed clinical and ECGmarkers to determine
their predictive role in VA/SCD risk in patients with BrS
and no prior cardiac arrest and to develop a risk score
model using easily acquired clinical markers.SEE PAGE 223
refractory period
VF = ventricular fibrillation
VT = ventricular tachycardiaMETHODS
STUDY DESIGN. This analysis was a multicenter in-
ternational cohort study involving a retrospective
evaluation of prospectively collected registries
including patients with BrS and no history of cardiac
arrest. The study conforms to the principles of the
Declaration of Helsinki. The authors from each
participating center guarantee the integrity of their
institution data and had approval from a local ethics
committee/internal review board. Subjects gave
informed consent in accordance with local protocol.
Baseline characteristics data were collected by us-
ing paper and electronic records. Sixteen clinical and
ECG markers were tested for their predictive role of
VA/SCD during follow-up (Table 1).
VARIABLE DEFINITIONS. Defini t ion of BrS . BrS
and a type 1 ECG pattern were defined as per guide-
lines (Supplemental Methods, Figure 1A) (10). Patients
with <1 year of follow-up were excluded.Genetics, Center for Cardiac Arrhythmias of Genetic Origin, IRCCS Istituto Au
Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universid
Cardiology andAngiology, HannoverMedical School, Hannover, Germany; mP
Italy; nDepartmentofCardiology, SantaMariaUniversityHospital, LisbonAcad
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pInstitute Saint Pierre, Perpignan, France; qClinique Pasteur, Toulouse, F
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The authors attest they are in compliance with human studies committe
institutions and Food and Drug Administration guidelines, including patien
visit the Author Center.
Manuscript received July 2, 2020; revised manuscript received August 13, 20Symptoms, co-morbidities, and family history. -
With the consensus of 2 senior cardiologists,
a syncopal episode was labeled as either
probable arrhythmia–related (PAR) or un-
likely arrhythmia–related syncope. A family
history of SCD was defined as unexpected
death at #45 years of age in a first-degree
relative with no known history of heart dis-
ease. A history of atrial fibrillation (AF)/atrial
flutter and sinus node disease (SND) was
recorded (Supplemental Methods).
ECG markers . The ECG reviewing process
and the definitions used for these markers are
detailed in the Supplemental Methods and
Figure 1 (11–15).
Cl in ica l invest igat ions . Patients who un-
derwent programmed ventricular stimulation
(16) (Supplemental Methods) and had poly-
morphic ventricular tachycardia (VT)/ven-
tricular fibrillation (VF) induced or a
ventricular effective refractory period
(VERP) <200 ms were identified. SCN5A gene
mutation carriers were also identified. The
use of programmed ventricular stimulation or genetic
testing was conducted per the center’s practice.
VA/SCD dur ing fol low-up. VA during follow-up
was defined as aborted SCD by cardioversion of VT/
VF or documented sustained VT (>200 beats/min) or
VF either on ambulatory Holter monitor, loop
recorder, and/or implantable cardioverter-
defibrillator (ICD) interrogation. SCD was defined if
there was a documented VA at the time of death or no
other cause was identified.
STATISTICAL ANALYSIS. The descriptive statistical
analysis method is outlined in the Supplemental
Methods.
Stat i s t i ca l models . Because this was a multicenter
study, the variability of each variable and the
outcome of VA/SCD during follow-up were analyzed
in accordance with the hospital site (Supplemental
Methods). Cox proportional hazards regressionxologico, Italiano, Milan, Italy; kArritmia, Instituto do
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TABLE 1 Factors Reviewed in the Cohort to Determine if They




Diagnosis by family screening of SCD
Spontaneous type 1 Brugada ECG pattern
SCN5A mutation




ER in peripheral leads
Type 1 Brugada ECG pattern in peripheral leads
aVR sign
Significant S-wave in lead I
QRS duration >120 ms in V2
QRS fragmentation
AF ¼ atrial fibrillation; aVR ¼ augmented vector right; BrS ¼ Brugada syndrome;
ECG ¼ electrocardiogram; ER ¼ early repolarization; SCD ¼ sudden cardiac death;
SND ¼ sinus node disease; VA ¼ ventricular arrhythmia; VERP ¼ ventricular
effective refractory period.
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212models were used to estimate the effect of the risk
factor on the outcome. Interactions with sex were
also assessed to determine whether separate models
were required for men and women. Country was notElectrocardiogram Markers Assessed as Potential Risk Factors for VA/SCD
lectrocardiograms that were assessed as potential risk factors for VAs/ in pa
cardiogram pattern. (B) Early repolarization. (C) Augmented vector right sign
d V1). SCD ¼ sudden cardiac death; VA ¼ ventricular arrhythmia.included as a risk factor to ensure that the model was
generalizable to other countries, but hospital was
included as a frailty term to account for the clustered
nature of the data. Schoenfeld residuals were used to
check for violations of the proportional hazards
assumption. Backward elimination was used as the
primary method to select predictors.
Risk score der ivat ion . From the final multivariable
model, a point-based score was derived, each factor
providing a number of points equal to its coefficient in
the model (i.e., the log[HR]) multiplied by 10. The total
score of a patient is the addition of the points from all
risk factors present in that patient. The exponential of
the total score divided by 10 is equal to the hazard ratio
(HR) of that patient compared with the HR of a patient
with no risk factors (the “reference” patient).
Est imat ion of r i sk of event . The actual risk of a
patient having an event within a particular follow-up
time depends on the risk of the reference patient
(reference risk) (Supplemental Methods).
In ternal va l idat ion of the model . Discrimination
was assessed by using Harrell’s C (HC) statistics.
Because of the multinational nature of the data, HC
statistics were estimated within each country
separately. If heterogeneity measures (I2) and teststients with Brugada syndrome (BrS) during follow-up. (A) Type 1
. (D) Peripheral type 1 Brugada electrocardiogram pattern. (E) QRS
TABLE 2 Baseline Characteristics
Whole Cohort (N ¼ 1110) Symptomatic (n ¼ 204) Asymptomatic (n ¼ 906) p Value
Age, yrs 51.8  13.6 51.5  16.1 50.9  14.7 0.63
Male 790 (71.2) 144 (70.6) 646 (71.3) 0.86
Ethnicity
White 936 (84.3) 175 (85.8) 761 (84.0) 0.59
African/Afro-Caribbean 21 (1.9) 4 (2.0) 17 (1.9) 1.00
South American 117 (10.5) 18 (8.8) 99 (10.9) 0.45
South Asian 20 (1.8) 4 (2.0) 16 (1.8) 0.77
East Asian 16 (1.4) 3 (1.5) 13 (1.4) 1.00
Other comorbidities
Hypertension 198 (17.8) 24 (11.8) 174 (19.2) 0.01
Type 2 diabetes 92 (8.3) 10 (4.9) 82 (9.1) 0.07
Dyslipidemia 150 (13.5) 25 (12.3) 125 (13.8) 0.65
CVA 45 (4.1) 6 (2.9) 39 (4.3) 0.44
Other noncardiac disease 95 (8.6) 2 (1.0) 93 (10.3) <0.001
Syncope 352 (32.0) / /
Unlikely arrhythmia related 148 (42.0)
Probable arrhythmia related 204 (58.0)
Mode of diagnosis
Suspected cardiac symptoms 410 (36.9) 155 (76.0) 255 (28.1) <0.001
Incidental diagnosis 462 (41.6) 26 (12.7) 436 (48.1) <0.001
Family screening of SCD 53 (4.8) 10 (4.9) 43 (4.7) 0.86
Family screening of BrS 174 (15.7) 13 (6.4) 161 (17.8) <0.001
Unknown 11 (1.0) 0 11 (1.2) 0.23
Type 1 Brugada ECG pattern
Spontaneous 388 (35.0) 117 (57.4) 271 (29.9) <0.001
Provocation 722 (65.0) 87 (42.6) 635 (70.1) <0.001
Ajmaline 462 (64.0) 57 (65.5) 405 (63.8) 0.81
Flecainide 225 (31.2) 23 (26.4) 202 (31.8) 0.34
Fever 35 (4.8) 7 (8.0) 28 (4.4) 0.33
Family history of SCD in first-degree relatives 235 (21.2) 51 (25.0) 184 (20.3) 0.15
Genetic testing 731 (65.9) 125 (61.3) 606 (66.9) 0.14
Programmed ventricular stimulation 406 (36.6) 77 (37.7) 329 (36.3) 0.75
VERP assessment 436 (39.3) 84 (41.2) 352 (38.9) 0.59
Primary prevention ICD 172 (15.5) 88 (43.1) 84 (9.3) <0.001
Values are mean  SD or n (%).
CVA ¼ cerebrovascular accident; ICD ¼ implantable cardioverter-defibrillator; other abbreviations as in Table 1.
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213suggest evidence of heterogeneity, an average across
all countries was then estimated with a random
effects model (Supplemental Methods). Calibration
was examined comparing 5-year predicted risks (us-
ing an average reference risk across the dataset) with
Kaplan-Meier estimated risks.
External validation with out-of-sample predictions. A
cross-validation according to country was used for
the external validation of the study risk score model
by removing each country to create the risk model




BASELINE CHARACTERISTICS. The study included
1,110 patients with BrS recruited across 16 centers in 8countries (United Kingdom, France, Germany, Spain,
Italy, Switzerland, Portugal, and Brazil) (Table 2). The
number of patients contributed by each hospital
varied from 3 to 262.
VA/SCD DURING FOLLOW-UP. The mean follow-up
time was 5.33  4.0 years. Of the 1,110 patients, 114
had a VA/SCD event (10.3%) during follow-up, with an
annual event rate of 1.5% (1.2% to 1.8%). Of the 114
patients with an event, 11 patients died of SCD (9.6%).
These patients were predominantly male (8 of 11), of
White ethnicity (10 of 11), had a BrS diagnosis after
investigation for syncope (6 of 11), and had sponta-
neous type 1 ECG (9 of 11). Of the 11 patients with SCD,
5 also had a history of PAR syncope, and 4 had a
family history of SCD. Seven of the 11 patients had
undergone programmed ventricular stimulation, and
this was positive in 2 patients.
TABLE 3 Differences in Proposed Risk Factors Between Those With VA/SCD Versus




(n ¼ 996) p Value
Age at diagnosis, yrs 43.2  16.0 43.7  13.4 0.85
Male 86 (75.4) 704 (70.7) 0.44
Probable arrhythmia–related syncope 67 (58.8) 137 (13.8) <0.001
Diagnosis by family screening of SCD 13 (11.4) 40 (4.1) 0.002
Spontaneous type 1 Brugada ECG pattern 89 (78.1) 299 (30.0) <0.001
Genetic testing 74 (64.9) 657 (66.0) 0.75
SCN5A mutation 21 (28.4) 154 (23.4) 0.39
Programmed ventricular stimulation 52 (45.6) 350 (35.1) 0.04
Inducible polymorphic VT or VF 23 (44.2) 105 (30.0) 0.06
VERP assessment 55 (48.2) 359 (36.0) 0.02
VERP <200 ms 11 (20.0) 77 (21.4) 1.00
SND 3 (2.6) 25 (2.5) 1.00
AF/atrial flutter 8 (7.0) 71 (7.1) 1.00
aVR sign 25 (21.9) 134 (13.5) 0.02
Significant S-wave in lead I 33 (28.9) 261 (26.2) 0.58
QRS duration >120 ms in V2 17 (14.9) 105 (10.5) 0.21
QRS fragmentation 12 (10.5) 88 (8.8) 0.60
Type 1 Brugada ECG pattern in peripheral leads 42 (36.8) 31 (3.1) <0.001
ER 43 (37.7) 72 (7.2) <0.001
Persistent 38 (88.4) 39 (54.2) <0.001
Follow-up, yrs 6.7  4.0 6.1  4.0 0.11
Values are mean  SD or n (%).
AF ¼ atrial fibrillation; VF ¼ ventricular fibrillation; VT ¼ ventricular tachycardia; other abbreviations as in
Table 1.
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214Of the 1,110 patients, 591 (53.2%) and 209 (18.8%)
patients completed 5 and 10 years of follow-up,
respectively. The following variables were signifi-
cantly more common in patients with a history of VA/
SCD compared with patients without VA/SCD during
follow-up: 1) PAR syncope; 2) a spontaneous type 1
Brugada ECG pattern; 3) early repolarization (ER) in
peripheral leads; and 4) a type 1 Brugada ECG pattern
in peripheral leads (Table 3).
Of the 1,110 patients, 70 (6.3%) had a history of PAR
syncope and none of the aforementioned additional
risk markers. Of these patients, 8 (11.4%) had VA/SCD
during follow-up, giving them an annual event rate of
1.30% (95% confidence interval [CI]: 0.60 to 2.46). In
the remaining 134 (12.1%) patients with PAR syncope
and the presence of 1 or more of the aforementioned
markers, 59 (44.0%) patients had an event during
follow-up (p < 0.001). The annual event rate in pa-
tients with PAR syncope which had none or a com-
bination of the other identified risk makers was 2.1%
(95% CI: 1.8 to 2.5). The annual event rate in patients
with PAR syncope and none of the other risk markers
was 1.0% (95% CI: 0.7 to 1.1).
Data heterogene i ty between hosp i ta l s . The het-
erogeneity test was significant for all 16 variables
tested according to hospital (Supplemental Table 1).Of the 1,110 patients, 731 (66.5%) underwent genetic
testing for SCN5A mutations, 406 (36.9%) received
programmed ventricular stimulation, and 436 (39.6%)
underwent VERP assessment. Because all patients did
not undergo these investigations, these variables
were not included when creating the risk score model
(Supplemental Results). They were not shown to be
significant predictors of VA/SCD on univariate anal-
ysis (Table 4).
RISK SCORE MODEL. The separate Cox proportional
hazards model for each variable showed that the
aforementioned 4 variables had strong statistical ev-
idence of association with VA/SCD during follow-up
(Table 4). These variables were incorporated into a
risk score model and were applicable across both
sexes. After external validation with out-of-sample
predictions, 4 of these variables showed a strong
significant effect in the separate and multivariable
models across all of the cross-validation samples with
stable HRs (Supplemental Tables 2 and 3 and
Supplemental Figure 1). The risk factor “Diagnosis by
family screening of SCD” did not show an effect when
the country Spain was removed from the estimation
sample. Exploring the data, it was found that this
factor was especially predictive for Spain, where the 9
patients who were diagnosed by using results of
family screening of SCD also had the outcome. This
variable was not included in the final model due to its
selective nature. The results from the cross-
validation by country justify the selection of the 4
risk factors discussed in the following sections.
PAR syncope . Patients with PAR syncope had a
lower mean restricted survival compared with pa-
tients without PAR syncope (7.7 years [95% CI: 7.0 to
8.4] vs. 9.6 years [95% CI: 9.4 to 9.7]; p < 0.001)
(Figure 2A). This revealed an HR of 3.71 (95% CI: 2.41
to 5.70; p < 0.001) for VA/SCD during follow-up. The
5-year predicted risk of event in patients with PAR
syncope and none of the other study identifiable risk
factors was 4.9%.
Spontaneous type 1 ECG pattern . Patients with a
spontaneous type 1 ECG pattern had a lower mean
restricted survival compared with patents without
this pattern (8.8 years [95% CI: 8.6 to 9.1] vs. 9.8
years [95% CI: 9.7 to 9.9]; p < 0.001) (Figure 2B). This
revealed an HR of 3.80 (95% CI: 2.31 to 6.24; p< 0.001).
The 5-year predicted risk of event in patients with
a spontaneous type 1 ECG pattern and none of
the other study identifiable risk factors was 5.9%.
ER in per iphera l leads . The presence of ER in pe-
ripheral leads resulted in a lower mean restricted
survival compared with patents without ER in pe-
ripheral leads (7.9 years [95% CI: 7.3 to 8.4] vs. 9.6
TABLE 4 HRs From Cox Regression Models and Derived Points Per Risk Factor
Separate Univariate Models Multivariate Model
Log(HR) ScoreHR 95% CI p Value HR 95% CI p Value
Age at diagnosis 1.00 0.99–1.01 0.90
Male 0.99 0.64–1.51 0.95
Probable arrhythmia–related syncope 5.92 4.05–8.63 <0.001 3.71 2.41–5.70 <0.001 1.15 12
Diagnosis by family screening of SCD 3.31 1.85–5.91 <0.001 4.56 2.39–8.71 <0.001
Spontaneous type 1 Brugada ECG pattern 5.93 3.71–9.48 <0.001 3.80 2.31–6.24 <0.001 1.38 14
SCN5A mutation 1.19 0.71–1.99 0.52
Positive programmed ventricular stimulation
(induction of polymorphic VT or VF)
1.46 0.83–2.54 0.19
VERp <200 ms 0.88 0.42–1.86 0.74
SND 1.01 0.32–3.20 0.99
AF/atrial flutter 0.91 0.44–1.86 0.79
ER in peripheral leads 6.07 4.12–8.94 <0.001 3.42 2.17–5.41 <0.001 1.21 9
Type 1 Brugada ECG pattern in peripheral leads 6.86 4.69–10.04 <0.001 2.33 1.48–3.67 <0.001 0.94 12
aVR sign 1.62 1.04–2.52 0.03
Significant S-wave in lead I 1.25 0.84–1.87 0.27
QRS interval >120 ms in V2 1.26 0.75–2.11 0.39
QRS fragmentation 1.09 0.61–1.95 0.77
CI ¼ confidence interval; HRs ¼ hazard ratios; other abbreviations as in Tables 1 and 3.
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215years [95% CI: 9.5 to 9.7]; p < 0.001) (Figure 2C). This
revealed an HR of 3.42 (95% CI: 2.17 to 5.41;
p < 0.001). The 5-year predicted risk of event in pa-
tients with ER in peripheral leads and none of the
other study identifiable risk factors was 4.9%.
Type 1 Brugada ECG pattern in peripheral leads. Patients
with a type 1 Brugada ECG pattern in peripheral leads
had a lower mean restricted survival compared with
patents without this pattern (7.71 years [95% CI: 7.0 to
8.4] vs. 9.6 years [95% CI: 9.4 to 9.7]; p < 0.001)
(Figure 2D). This revealed an HR of 2.33 (95% CI: 1.48
to 3.67; p < 0.001). The 5-year predicted risk of event
in patients with a type 1 Brugada ECG pattern in pe-
ripheral leads and none of the other study identifiable
risk factors was 3.6%.
RISK SCORE. Calculator http://brugadariskscore.com.
The final risk score model consisted of the 4 variables,
which were binary, whereby a “yes” value increased
the hazard. An automatic backward step algorithm
also produced the same model. The Schoenfeld re-
siduals analysis did not show any evidence against
the proportional hazards assumptions (all p values
were >0.05; for the global test; p ¼ 0.27). Each of the 4
variables was allocated a point score based on the
predictive strength of the variable, with the possi-
bility of a maximum score of 47 points (Tables 4 and 5,
Central Illustration). Using the Central Illustration and
Supplemental Table 4, the total points obtained from
the risk score model for a patient can be translated
into the predicted risk of VA/SCD during 5 years offollow-up. Supplemental Table 5 also shows by how
much the 5-year predicted risk of events would in-
crease (in the average model) for having the risk
factor of interest without any of the other identified
risk factors or in the presence of different combina-
tions of the other 3 identified risk factors. For
example, a patient with a spontaneous type 1 ECG
pattern has an additional increased 5-year predicted
risk of 2.1% compared with a patient with a non-
spontaneous type 1 ECG pattern and none of the other
identified risk factors. The distribution of number of
risk factors per country is presented in Supplemental
Figure 2.
RISK SCORE MODEL DISCRIMINATION AND
CALIBRATION. The HC statistics showed strong het-
erogeneity between countries (I2 ¼ 86%; p < 0.01)
both in-sample and out-of-sample. The random ef-
fects average HC statistics across countries was 0.88
(95% CI: 0.82 to 0.95) and 0.88 (95% CI: 0.81 to 0.94)
for in-sample and out-of-sample predictions, respec-
tively (Supplemental Figures 3A and 3B).
Hosmer-Lemeshow (HM) plots according to coun-
try showed a good correlation between the predicted
risk with the study model and observed risk estimated
by using a Kaplan-Meier analysis for in-sample and
out-of-sample predictions, particularly when cali-
brating the score to country (Supplemental Figures 4A
and 4B, Supplemental Table 6). Calibration according
to risk level also showed a good correlation
between predicted and observed risk for in-
sample and out-of-sample predictions (Supplemental
FIGURE 2 KM Curves Showing Survival Free of VA/SCD Events According to Presence or Absence of the 4 Identified Risk Markers
Kaplan-Meier curves showing survival free from ventricular arrhythmias/sudden cardiac death in patients with Brugada syndrome when comparing the presence and
absence of the 4 risk markers identified. (A)With and without probable arrhythmia–related syncope; (B) with and without spontaneous type 1 Brugada electrocardiogram
(ECG) pattern; (C) with and without early repolarization in peripheral leads; and (D) with and without a type 1 Brugada ECG pattern in peripheral leads. The curves show
lower ventricular arrhythmia/sudden cardiac death survival in those with probable risk markers compared with those without. The table below each Kaplan-Meier curves
shows the number at risk for each time period. KM ¼ Kaplan-Meier; other abbreviations as in Figure 1.
Honarbakhsh et al. J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 7 , N O . 2 , 2 0 2 1
Brugada Syndrome Risk Stratification F E B R U A R Y 2 0 2 1 : 2 1 0 – 2 2
216

















0 0 0 0 0 1.5
1 0 0 0 9 3.6
0 1 0 0 12 4.9
0 0 1 0 12 4.9
0 0 0 1 14 5.9
1 1 0 0 21 11.5
1 0 1 0 21 11.5
1 0 0 1 23 13.9
0 1 1 0 24 15.2
0 1 0 1 26 18.3
0 0 1 1 26 18.3
1 1 1 0 33 33.4
1 1 0 1 35 39.1
1 0 1 1 35 39.1
0 1 1 1 38 48.8
1 1 1 1 47 80.7
The table shows all possible risk factor combinations in the data and their associated score points.
Abbreviations as in Table 1.
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217Results, Supplemental Figures 5A and 5B, and
Supplemental Table 7).
Recalibration regression showed a significant het-
erogeneity in the recalibration needs between coun-
tries (Supplemental Figures 6A and 6B), likely
accounted for by the differences in average scores
and survival rates between countries (Supplemental
Table 8 and Supplemental Figures 3A and 3B).
Figure 3 illustrates the simulated effect of using
different thresholds of 5-year VA/SCD risk to implant
an ICD. This enables one to identify specific cut points
at which the cost-efficacy of ICD implantation could
be determined and optimal thresholds to protect the
greatest number of patients appropriately. Assuming
that an ICD implant will effectively treat the VA event
to prevent SCD, at the threshold of 3% at 5-year risk
prediction, the number needed to treat (NNT) with an
ICD to save 1 life was 8 and 9 in uncalibrated and
calibrated models, respectively. At the 5% and 10%
threshold, this would be 7 (8 with calibrated model)
and 5 patients. The risk score model incorporating the
4 identified risk factors showed a sensitivity of 71.2%
(95% CI: 61.5% to 84.6%) and a specificity of 80.2%
(95% CI: 75.7% to 82.3%) in predicting VA/SCD at 5
years when using the 10% cutoff threshold.
RISK SCORE MODEL IN PATIENTS WITHOUT PRIOR
PAR SYNCOPE. The in-sample HC statistics of the
model was 0.80 (95% CI: 0.72 to 0.88) in patients
without previous PAR syncope. There was also a good
correlation between the predicted and the observed
risk, with a mean prediction error of 2.46% at 5 years
of follow-up. The risk model showed a sensitivity of
68.2% and a specificity of 61.0% in predicting VA/SCD
in patients without prior PAR syncope when using a
cutoff of 5% predicted risk with calibrated models
(Supplemental Figure 7).
DISCUSSION
Through this multicenter international study, the role
of 16 proposed risk factors for VA/SCD in BrS was
evaluated in one of the largest BrS cohorts published
to date. Many factors previously proposed from small
single-center cohorts did not play such an important
role in this primary prevention cohort, whereas other
less frequently reported markers are more important
predictors of VA/SCD. By incorporating these factors
into a risk score model, we have developed a scoring
system that has a high predictive power.
PAR syncope and a spontaneous type 1 Brugada
ECG pattern remain independent predictors of VA/
SCD compatible with the findings of numerous BrS
studies (2,6,17–19). Interestingly, the presence of ERand a type 1 Brugada ECG pattern in peripheral leads,
which has previously only been assessed in a few
studies, were shown to be independent predictors of
VA/SCD in this cohort (12,20–22).
This study is the first, to the best of our knowledge,
that assessed all 16 proposed risk factors in a single
study; others have only assessed the role of <10
proposed risk factors (2,17,18,23). We were able to
assess the comparative predictive accuracy of each
marker in a multicenter population in which center-
specific selection biases are less likely to operate.
This is a limitation of single-center studies that have
only focused on a smaller number of risk factors and
the effects of referral bias and disease severity in
specific families may operate. Furthermore, by
including patients from 15 European centers, it allows
the establishment of a cohort that should better
represent a general BrS population, making the find-
ings more applicable in European subjects.
The study findings are compatible with those of
Delise et al. (19), who also evaluated risk factors for
VA/SCD in a primary prevention BrS cohort. Both
studies have shown that syncope and spontaneous
type 1 ECG were predictors of VA/SCD during follow-
up on multivariate analysis and that the presence of
additional risk factors resulted in a higher risk of VA/
SCD. However, the remaining 3 risk factors that were
identified in the current study were not evaluated by
Delise et al. (19), and it therefore remains unclear
whether these markers would have also been pre-
dictors of VA/SCD during follow-up in that cohort.
CENTRAL ILLUSTRATION Brugada Risk Calculator: http://brugadariskscore.com: Risk Score Calculation and
Predicted Event Rates Presented Graphically Over 5 Years
Honarbakhsh, S. et al. J Am Coll Cardiol EP. 2021;7(2):210–22.
The total number of points for a patient is added up in accordance to the variables present and represented on the x-axis. The red curve above it estimates the predicted
risk of ventricular arrhythmias (VAs)/sudden cardiac death (SCD) for the patients in the whole cohort during a 5-year follow-up. The dots on the curves represent actual
values that a patient can be assigned with a combination of the 4 variables. BrS ¼ Brugada Syndrome; ECG ¼ electrocardiogram; ER ¼ early repolarization.
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cross-validation according to country was performed.
The evaluation consistently showed that the 4 risk
factors included in the risk score model exhibit
consistent results across all cross-validation samples.
These findings thereby justify the selection of the risk
factors and the coefficients of this model. When
applying models developed in 1 country/setting to a
different one, it is important to determine whether
recalibration of the model to the new country/set-
ting’s rate of events and average score is needed. As
shown with this model, the recalibration needs of a
country were variable, again emphasizing theimportance of model recalibration. Models are
frequently applied in a new setting without recali-
bration partly due to the absence of data to recali-
brate. As shown in this study, the risk score model
can be used effectively in different countries; it is
important to highlight, however, that it might
perform even better if it was recalibrated to the
country it was applied to using mean risk scores and
5-year mean survival.
In the current study, there was a significant dif-
ference in the prevalence of certain variables across
hospitals. Further to this, the observed event rate
among countries also varied. These findings
FIGURE 3 Impact of the Risk Prediction Model on Clinical Decision-Making
The bars represent the proportion of patients who would have received an implantable cardioverter-defibrillator (ICD) (right of 0) and those who would have not (left of
0) at specific risk thresholds. Each of the 2 proportions is further divided into patients with and without ventricular arrhythmia (VA)/sudden cardiac death (SCD) events at
the end of the 5-year follow-up. Sensitivity (Sens.), Specificity (Spec.), positive predictive values (PPVs), and negative predictive values (NPVs) are also presented for the
model when applied at the different risk levels. The figure also shows the differences in these parameters whether the risk score model is used calibrated (C-Calib) or
uncalibrated (UnCalib).
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horts among hospitals and countries. Therefore,
when establishing a risk score model in a single center
such as that of the Sieira et al. (23) risk score model,
this heterogeneity is not taken into consideration.
Since the risk score model in this study was estab-
lished by using cohorts across 8 countries and 16
centers, it ensures a better representation of a more
generalized BrS cohort.
PROGRAMMED STIMULATIONAND GENETIC TESTING. Due
to the controversial nature of programmed ventricu-
lar stimulation as a risk factor for VA/SCD in BrS
(2,6,18,20,24), it is not strongly recommended in
clinical guidelines (10); only 406 patients (37%) in the
current cohort underwent programmed ventricular
stimulation as in other published studies (24), and 66%
underwent SCN5A mutation testing, compatible with
previous studies (6,23). Thereby, the findings from
these investigations were not included in thedevelopment of the final risk score model during
multivariate analysis. The risk score model of Sieira
et al. (23) assigned inducible VA on programmed ven-
tricular stimulation as a risk marker in their risk score
model even though it was only determined
on univariate analysis. In the current cohort, 37%
(n ¼ 406) of the patients underwent programmed
ventricular stimulation versus 91% (n ¼ 364) in the
study by Sieira et al. (23), which still accounts for a large
number of patients. On the univariate analysis in this
study, this factor was not shown to be predictive of VA/
SCD.
Programmed ventricular stimulation in this study
was performed in accordance with the protocol of
Wellens et al. (16), which involved triple extrastimuli
and is consistent with that used by Sieira et al. (23).
There is currently no clear consensus on what pro-
tocol is most appropriate for evaluating VA induc-
ibility (18). This is further highlighted by the pooled
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included use either single, double, or triple extra-
stimuli during programmed ventricular stimulation.
This pooled analysis concluded that using triple
extrastimuli during programmed ventricular stimu-
lation as used in the creation of this model was not as
specific as using double extrastimuli; however, they
did show that VA induction using triple extrastimuli
was significantly associated with cardiac arrest or
appropriate ICD shock during follow-up. Sieira et al.
(23) also used triple extrastimuli, which they showed
was predictive of VA/SCD. Therefore, the lack of
predictive power of a positive programmed ventric-
ular stimulation in this study cannot solely be
accounted for by the stimulation protocol used. This
does, however, highlight a major limitation of incor-
porating findings from programmed ventricular
stimulation into a risk score model. First, its role re-
mains controversial and is not recommended
routinely in the current guidelines. Second, if the
stimulation protocol utilized is dictated by that used
during the model development, this might require
centers to alter their clinical practice to be able to
adopt the model. The model created in this study
incorporates markers that can be evaluated from
clinical history and a baseline ECG and thus is not
influenced by the limitations as discussed here.
Although we found no association with SCN5A
mutation status and risk, it is recognized that specific
mutations may be more malignant or specific haplo-
types confer greater risk of VA events (e.g., Nav1.5
protein truncating mutations [23,25]).
ER AND PERIPHERAL BRUGADA ECG FEATURES. In
this cohort, ER was shown to be associated with a
higher risk of VA/SCD in patients with BrS, which is
consistent with the findings of other studies in BrS
(20–22) and idiopathic VF (26,27). The role of a type 1
Brugada ECG pattern in peripheral leads as a risk
factor for VA/SCD in BrS has only been assessed in 1
other study (13). It is plausible that the presence of a
type 1 Brugada/ER ECG pattern in peripheral leads is
indicative of a higher “ER burden” and thereby ac-
counts for the higher VA/SCD risk when present,
analogous to prolonged repolarization in long QT
syndrome (28).
SYNCOPE. PAR syncope alone was associated with
significantly fewer events compared with the addi-
tion of 1 or more of the other 4 identified risk markers.
PAR syncope alone was associated with a predicted
risk of VA/SCD during follow-up of 5%. Because many
large studies have not evaluated for the presence ofall the risk markers identified in this study, it is un-
clear whether the other risk markers did coexist in
these patients and that the high event rate identified
is solely accounted for by the presence of a history of
syncope. Patients with PAR syncope and none of the
other study-identifiable risk factors fall in the pre-
dicted risk group >3%. In the current clinical guide-
lines, a Class IIa recommendation is provided for
primary prevention ICD implantation in these pa-
tients. As shown in this study, if ICD implantation
was restricted to patients above the predicted risk
group >5%, not only is the NNT to prevent an event
lower, but a smaller proportion of patients end up
with ICD implantation without experiencing an event
compared with the predicted risk group > 3%. How-
ever, as the predicted risk is just below the risk level
>5%, clinicians should use their discretion along with
guideline recommendations when deciding whether
ICD implantation should be considered in these pa-
tients. The same argument applies with a sponta-
neous type 1 Brugada ECG pattern, which was
associated with a predicted risk of 5.9% (which is just
above 5%). This risk becomes significantly multiplied
when combined with the other markers. The exact
risk threshold to implant an ICD is at the discretion of
the physician and shared decision-making with the
patient.
CLINICAL IMPLICATIONS. The utilization of this
score enables more accurate quantification of risk in
asymptomatic BrS patients and risk thresholds to
optimize ICD prescription. The risk score shows that
in BrS at the 3% risk threshold, the NNT is 9 at 5 years.
The exact thresholds selected will vary according to
patient, physician-determined risk:benefit thresh-
olds, and health policy.
STUDY LIMITATIONS. Due to the retrospective nature
of this study, there is a risk of recall bias. However, to
overcome the low incidence rate of VA/SCD in BrS and
the need for long-term follow-up, using a multicenter
international cohort enables establishment of a cohort
that is more representative of a general BrS popula-
tion. Because not all patients underwent programmed
ventricular stimulation, VERP assessment, and ge-
netic mutation testing, these factors were not
included in the Cox regression model. However, the
univariate analysis did not show a predictive role for
these factors, and there was no significant difference
in the VA/SCD rate in those with or without these
factors, and thus they are unlikely to be of
significance.
PERSPECTIVES
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221FUTURE DEVELOPMENTS. The incremental predic-
tive value of environmental, social factors, including
access to health care and genetic information, could
be examined in future iterations of this model. The
ultimate test of the usefulness of a prediction model
is an impact study that determines whether the
model improves decision-making, patient outcomes,
and cost-effectiveness.COMPETENCY IN MEDICAL KNOWLEDGE: Risk stratifica-
tion for primary prevention of SCD in BrS is a significant chal-
lenge due to the low event rates and conflicting evidence. By
reviewing 16 major proposed risk markers in a multicenter in-
ternational BrS cohort over a long follow-up period, 4 markers
(PAR syncope, type 1 spontaneous ECG, ER in the peripheral
leads, and type 1 ECG Brugada pattern in peripheral leads) were
shown to play a significant role in the risk stratification of VA/
SCD in BrS. A risk score model using these markers revealed high
sensitivity and specificity in predicting VA/SCD during follow-up.
TRANSLATIONAL OUTLOOK: Through this multicenter in-
ternational study, it has been shown that 4 markers are associ-
ated with a higher risk of VA/SCD in patients with BrS during
follow-up. A risk score model that incorporated these markers
can be used in clinical practice to improve the predictive accuracy
of primary prevention ICD recommendations and allow individ-
ualized risk stratification.CONCLUSIONS
By reviewing major proposed risk factors in a multi-
center BrS cohort over a long follow-up period, 4
factors were shown to play a significant role in the
risk stratification of VA/SCD in BrS. A risk score model
using these factors was strongly predictive of VA/SCD
in BrS. Utilizing this model in clinical practice could
improve the predictive accuracy of primary preven-
tion ICD recommendations and allow individualized
risk stratification.
FUNDING SUPPORT ANDAUTHOR DISCLOSURES
Dr. Lambiase is supported by the Stephen Lyness Memorial Fund,
UCLH Biomedicine National Institutes of Health Research, Barts
Biomedical Research Centre; and has obtained research grants and
speaker fees from Medtronic, Abbott, and Boston Scientific. All other
authors have reported that they have no relationships relevant to the
contents of this paper to disclose.ADDRESS FOR CORRESPONDENCE: Dr. Pier D. Lam-
biase, Institute of Cardiovascular Science, University
College London, The Barts Heart Centre, West
Smithfield, London EC1A 7BE, United Kingdom.
E-mail: p.lambiase@ucl.ac.uk.RE F E RENCE S1. Mizusawa Y, Wilde AA. Brugada syndrome. Circ
Arrhythm Electrophysiol 2012;5:606–16.
2. Probst V, Veltmann C, Eckardt L, et al. Long-
term prognosis of patients diagnosed with Bru-
gada syndrome: results from the FINGER Brugada
Syndrome Registry. Circulation 2010;121:635–43.
3. Adler A, Rosso R, Chorin E, Havakuk O,
Antzelevitch C, Viskin S. Risk stratification in Bru-
gada syndrome: clinical characteristics, electro-
cardiographic parameters, and auxiliary testing.
Heart Rhythm 2016;13:299–310.
4. Sacher F, Arsac F, Wilton SB, et al. Syncope in
Brugada syndrome patients: prevalence, charac-
teristics, and outcome. Heart Rhythm 2012;9:
1272–9.
5. Olde Nordkamp LR, Vink AS, Wilde AA, et al.
Syncope in Brugada syndrome: prevalence, clinical
significance, and clues from history taking to
distinguish arrhythmic from nonarrhythmic causes.
Heart Rhythm 2015;12:367–75.
6. Priori SG, Gasparini M, Napolitano C, et al. Risk
stratification in Brugada syndrome: results of the
PRELUDE (PRogrammed ELectrical stimUlation
preDictive valuE) registry. J Am Coll Cardiol 2012;
59:37–45.
7. Brugada J, Brugada R, Brugada P. Determinants
of sudden cardiac death in individuals with theelectrocardiographic pattern of Brugada syndrome
and no previous cardiac arrest. Circulation 2003;
108:3092–6.
8. Priori SG, Napolitano C, Gasparini M, et al.
Natural history of Brugada syndrome: insights for
risk stratification and management. Circulation
2002;105:1342–7.
9. Eckardt L, Probst V, Smits JP, et al. Long-term
prognosis of individuals with right precordial ST-
segment-elevation Brugada syndrome. Circula-
tion 2005;111:257–63.
10. Priori SG, Wilde AA, Horie M, et al. Executive
summary: HRS/EHRA/APHRS expert consensus
statement on the diagnosis and management of
patients with inherited primary arrhythmia syn-
dromes. Europace 2013;15:1389–406.
11. Macfarlane PW, Antzelevitch C,
Haissaguerre M, et al. The early repolarization
pattern: a consensus paper. J Am Coll Cardiol
2015;66:470–7.
12. Babai Bigi MA, Aslani A, Shahrzad S. aVR sign
as a risk factor for life-threatening arrhythmic
events in patients with Brugada syndrome. Heart
Rhythm 2007;4:1009–12.
13. Rollin A, Sacher F, Gourraud JB, et al. Preva-
lence, characteristics, and prognosis role of type 1ST elevation in the peripheral ECG leads in pa-
tients with Brugada syndrome. Heart Rhythm
2013;10:1012–8.
14. Morita H, Kusano KF, Miura D, et al. Frag-
mented QRS as a marker of conduction abnor-
mality and a predictor of prognosis of Brugada
syndrome. Circulation 2008;118:1697–704.
15. Calo L, Giustetto C, Martino A, et al. A new
electrocardiographic marker of sudden death in
brugada syndrome: the S-wave in lead I. J Am Coll
Cardiol 2016;67:1427–40.
16. Wellens HJ, Brugada P, Stevenson WG. Pro-
grammed electrical stimulation of the heart in
patients with life-threatening ventricular arrhyth-
mias: what is the significance of induced arrhyth-
mias and what is the correct stimulation protocol?
Circulation 1985;72:1–7.
17. Sieira J, Ciconte G, Conte G, et al. Asymp-
tomatic Brugada syndrome: clinical characteriza-
tion and long-term prognosis. Circ Arrhythm
Electrophysiol 2015;8:1144–50.
18. Sroubek J, Probst V, Mazzanti A, et al. Pro-
grammed ventricular stimulation for risk stratifi-
cation in the Brugada syndrome: a pooled analysis.
Circulation 2016;133:622–30.
19. Delise P, Allocca G, Marras E, et al. Risk
stratification in individuals with the Brugada type 1
Honarbakhsh et al. J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 7 , N O . 2 , 2 0 2 1
Brugada Syndrome Risk Stratification F E B R U A R Y 2 0 2 1 : 2 1 0 – 2 2
222ECG pattern without previous cardiac arrest: use-
fulness of a combined clinical and electrophysio-
logic approach. Eur Heart J 2011;32:169–76.
20. Kamakura S, Ohe T, Nakazawa K, et al. Long-
term prognosis of probands with Brugada-pattern
ST-elevation in leads V1-V3. Circ Arrhythm Elec-
trophysiol 2009;2:495–503.
21. Takagi M, Aonuma K, Sekiguchi Y, et al. The
prognostic value of early repolarization (J wave)
and ST-segment morphology after J wave in Bru-
gada syndrome: multicenter study in Japan. Heart
Rhythm 2013;10:533–9.
22. Kawata H, Morita H, Yamada Y, et al. Prog-
nostic significance of early repolarization in
inferolateral leads in Brugada patients with
documented ventricular fibrillation: a novel risk
factor for Brugada syndrome with ventricular
fibrillation. Heart Rhythm 2013;10:1161–8.23. Sieira J, Conte G, Ciconte G, et al. A score
model to predict risk of events in patients with
Brugada Syndrome. Eur Heart J 2017;38:1756–63.
24. Paul M, Gerss J, Schulze-Bahr E, et al. Role of
programmed ventricular stimulation in patients with
Brugada syndrome: a meta-analysis of worldwide
published data. Eur Heart J 2007;28:2126–33.
25. Sommariva E, Pappone C, Martinelli
Boneschi F, et al. Genetics can contribute to the
prognosis of Brugada syndrome: a pilot model
for risk stratification. Eur J Hum Genet 2013;21:
911–7.
26. Haissaguerre M, Derval N, Sacher F, et al.
Sudden cardiac arrest associated with early repo-
larization. N Engl J Med 2008;358:2016–23.
27. Honarbakhsh S, Srinivasan N, Kirkby C, et al.
Medium-term outcomes of idiopathic ventricularfibrillation survivors and family screening: a
multicentre experience. Europace 2017;19:
1874–80.
28. Viskin S, Adler A, Rosso R. Brugada burden
in Brugada syndrome: the way to go in
risk stratification? Heart Rhythm 2013;10:
1019–20.KEY WORDS Brugada syndrome, inherited
channelopathy, sudden cardiac death,
ventricular arrhythmiaAPPENDIX For supplemental Methods,
Results, figures, and tables, please see the
online version of this paper.
